NSG 6430 MIDTERM EXAM / NSG6430 MIDTERM EXAM (NEWEST, UPDATED) | COMPLETE SOLUTION|
NSG 6430 MIDTERM EXAM / NSG6430 MIDTERM EXAM (NEWEST, UPDATED) | COMPLETE SOLUTION| additional calories while BF? - Answer 450-500 Associated conditions with Fibromyalgia - Answer CFS, IBS, HAs, Mood DOs, unexplained pelvic pain, bladder dysfunction, TMJ Capacitation - Answer sperm's ability to fertilize egg CD4 count - Answer also known as T-4 cell count of helper lymphocyte count -used to assess competence of patient's immune system 200 meets CDC definition of AIDS clitoral hypertrophy, severe hirsutism, deepening voice, increase muscle mass, breast atrophy, male pattern baldness - Answer virilization Decreasing kcal by BMI? - Answer BMI 35, dec kcal by 500 per day BMI 35 dec kcal by 500-1,000 per day excessive terminal hair growth in women occurs in anatomic areas where hair follicles most androgen sensitive - Answer hirsutism Fibromyalgia - Answer 3 months c/o pain -individual with both widespread pain and at least 11 of 18 possible tender points First medication for HIV? - Answer AZT or Zidovudine in 1987 Gastric bypass surgery absorption problems - Answer iron and calcium- occurs in duodenum Highest prevalence of women with HIV - Answer AA and hispanics AA prev. rate nearly 4x that of white women HIV risks- percutaneous exposure and exposure to mucous membranes - Answer percutaneous exposure to HIV infected blood: 0.3% mucous membrane transmission: 0.09% HIV/AIDS related illness leading cause of death among who? - Answer black women ages 25-34 LDL, A1c, Tgl, FBS for DM women - Answer FBS 80-120; bedtime 100-140 Hgb A1C 7% LDL 100
Geschreven voor
- Instelling
- NSG 6430
- Vak
- NSG 6430
Documentinformatie
- Geüpload op
- 23 februari 2025
- Aantal pagina's
- 3
- Geschreven in
- 2024/2025
- Type
- Tentamen (uitwerkingen)
- Bevat
- Vragen en antwoorden
Onderwerpen
-
normal bmi
-
overweight bmi
-
obese bmi
-
morbidly obese bmi
-
decreasing kcal by bmi
-
first medication for hiv
-
screening test for hiv
-
mother child hiv transmission
-
hiv risks percutaneous exposure and exposur